参考文献/References:
[1] NCD Risk Factor Collaboration. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults[J]. The Lancet, 2017, 390(10113): 2627-2642.
[2] Lobstein T, Brownell K D. Endocrine-disrupting chemicals and obesity risk: A review of recommendations for obesity prevention policies[J]. Obesity Reviews, 2021, 22(11): e13332.
[3] Ahmed B, Sultana R, Greene M W. Adipose tissue and insulin resistance in obese[J]. Biomedicine and Pharmacotherapy, 2021, 137: 111315.
[4] Perrone A, Giovino A, Benny J, et al. Advanced Glycation End Products (AGEs): Biochemistry, Signaling, Analytical Methods, and Epigenetic Effects[J]. Oxidative Medicine and Cellular Longevity, 2020, 2020: 3818196.
[5] Ruiz H H, Ramasamy R, Schmidt A M. Advanced glycation end products: Building on the concept of the "common soil" in metabolic disease[J]. Endocrinology, 2020, 161(1): 6.
[6] Zaki M, Kamal S, KholouaI S, et al. Serum soluble receptor of advanced glycation end products and risk of metabolic syndrome in Egyptian obese women[J]. EXCLI Journal, 2017, 16: 973-980.
[7] Ppasad K. AGE-RAGE stress: a changing landscape in pathology and treatment of Alzheimers disease [J]. Molecular and Cellular Biochemistry, 2019, 459(1-2): 95-112.
[8] Semchyshyn H. Is carbonyl/AGE/RAGE stress a hallmark of the brain aging?[J]. European Journal of Physiology, 2021, 473(5): 723-734.
[9] Ega?-Gorro? L, López-Diez R, Yepuri G, et al. Receptor for advanced glycation end products (RAGE) and mechanisms and therapeutic opportunities in diabetes and cardiovascular disease: Insights from human subjects and animal models[J]. Frontiers in Cardiovascular Medicine, 2020, 7: 37.
[10] Wu X Q, ZhangD D, Wang Y N, et al. AGE/RAGE in diabetic kidney disease and ageing kidney[J]. Free radical Biology and Medicine, 2021, 171: 260-271.
[11] Hofmann M A, Drury S, Hhdson B I, et al. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response[J]. Genes and Immunity, 2002, 3(3): 123-135.
[12] Chen D Y, Chen Y M, Lin C C, et al. The potential role of advanced glycation end products (AGEs) and soluble receptors for AGEs (sRAGE) in the pathogenesis of adult-onset stills disease[J]. BMC Musculoskeletal Disorders, 2015, 16: 111.
[13] Sanajou D, Ghorbani HAGHJO A, Argani H, et al. AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions[J]. European Journal of Pharmacology, 2018, 833: 158-164.
[14] Pathomthongtaweechai N, Chutipongtanate S. AGE/RAGE signaling-mediated endoplasmic reticulum stress and future prospects in non-coding RNA therapeutics for diabetic nephropathy[J]. Biomedicine and Pharmacotherapy, 2020, 131: 110655.
[15] Ahmad S, Khan H, Siddiqui Z, et al. AGEs, RAGEs and s-RAGE friend or foe for cancer[J]. Seminars in Cancer Biology, 2018, 49: 44-55.
[16] Muthyalaiah Y S, Jonnalagadda B, John C M, et al. Impact of advanced glycation end products (AGEs) and its receptor (RAGE) on cancer metabolic signaling pathways and its progression[J]. Glycoconjugate Journal, 2021, 38(6): 717-734.
[17] Mollace A, Coluccio M L, Donato G, et al. Cross-talks in colon cancer between RAGE/AGEs axis and inflammation/immunotherapy[J]. Oncotarget, 2021, 12(13): 1281-1295.
[18] Corica D, Aversa T, Ruggeri R M, et al. Could AGE/RAGE-Related Oxidative Homeostasis Dysregulation Enhance Susceptibility to Pathogenesis of Cardio-Metabolic Complications in Childhood Obesity[J]. Frontiers in Endocrinology, 2019, 10: 426.
[19] Bettiga A, Fiorio F, DI Marco F, et al. The modern western diet rich in advanced glycation end-products (AGEs): An overview of its impact on obesity and early progression of renal pathology[J]. Nutrients, 2019, 11(8): 1748.
[20] Cinco E D R, Madrigal B R, Rosales J A D, et al. Expression of the receptor of advanced glycation end-products (RAGE) and membranal location in peripheral blood mononuclear cells (PBMC) in obesity and insulin resistance[J]. Iranian Journal of Basic Medical Sciences, 2019, 22(6): 623-630.
[21] Garay-Sevilla M E, Torres-Graciano S, Villegas-rodriguez M E, et al. Advanced glycation end products and their receptors did not show any association with body mass parameters in metabolically healthy adolescents[J]. Acta Paediatrica, 2018, 107(12): 2146-2151.
[22] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J]. European Journal of Epidemiology, 2010, 25(9): 603-605.
[23] Gurecká R, Koborová I, Csongová M, et al. Correlation among soluble receptors for advanced glycation end-products, soluble vascular adhesion protein-1/semicarbazide-sensitive amine oxidase (sVAP-1) and cardiometabolic risk markers in apparently healthy adolescents: a cross-sectional study[J]. Glycoconjugate Journal, 2016, 33(4): 599-606.
[24] Davis K E, Prasad C, Vijayagopal P, et al. Serum soluble receptor for advanced glycation end products correlates inversely with measures of adiposity in young adults[J]. Nutrition Research, 2014, 34(6): 478-485.
[25] Chiavaroli V, Dadamo E, Giannini C, et al. Serum levels of receptors for advanced glycation end products in normal-weight and obese children born small and large for gestational age[J]. Diabetes Care, 2012, 35(6): 1361-1363.
[26] Zaki M, Kamal S, Kholousi S, et al. Serum soluble receptor of advanced glycation end products and risk of metabolic syndrome in egyptian obese women[J]. Excli Journal, 2017, 16: 973-980.
[27] Piché M E, Tchernof A, Després J P. Obesity Phenotypes, Diabetes, and Cardiovascular Diseases[J]. Circulation Research, 2020, 126(11): 1477-1500.
[28] Yonekura H, Yamamoto Y, Sakurai S, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury[J]. The Biochemical Journal, 2003, 370(Pt 3): 1097-109.
[29] Dadamo E, Giannine C, Chiavaroli V, et al. What is the significance of soluble and endogenous secretory receptor for advanced glycation end products in liver steatosis in obese prepubertal children?[J]. Antioxid Redox Signal, 2011, 14(6): 1167-1172.
[30] Gaens K H J, Stehouwer C D A, Schalkwijk C G. Advanced glycation endproducts and its receptor for advanced glycation endproducts in obesity[J]. Current Opinion in Lipidology, 2013, 24(1): 4-11.
[31] Ramasamy R, Yan S F, Schmidt A M. The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes[J]. Vascular Pharmacology, 2012, 57(5-6): 160-167.
[32] Uchida Y, Ohba K, Yoshioka T, et al. Cellular carbonyl stress enhances the expression of plasminogen activator inhibitor-1 in rat white adipocytes via reactive oxygen species-dependent pathway[J]. Journal of Biological Chemistry, 2004, 279(6): 4075-4083.
[33] Chen C Y, Abell A M, Moon Y S, et al. An advanced glycation end product (AGE)-receptor for AGEs (RAGE) axis restores adipogenic potential of senescent preadipocytes through modulation of p53 protein function[J]. Journal of Biological Chemistry, 2012, 287(53): 44498-44507.
[34] Ueno H, Koyama H, Shoji T, et al. Receptor for advanced glycation end-products (RAGE) regulation of adiposity and adiponectin is associated with atherogenesis in apoE-deficient mouse[J]. Atherosclerosis, 2010, 211(2): 431-436.
[35] Dozio E, Briganti S, Delnevo A, et al. Relationship between soluble receptor for advanced glycation end products (sRAGE), body composition and fat distribution in healthy women[J]. European Journal of Nutrition, 2017, 56(8): 2557-2564.
[36] Yamagishi S I, Sotokawauchi A, Matsui T. Pathological role of advanced glycation end products (AGEs) and their receptor axis in atrial fibrillation[J]. Mini Reviews in Medicinal Chemistry, 2019, 19(13): 1040-1048.
[37] Shen C Y, Lu C H, Wu C H, et al. The development of maillard reaction, and advanced glycation end product (AGE)-receptor for AGE (RAGE) signaling inhibitors as novel therapeutic strategies for patients with AGE-related diseases[J]. Molecules, 2020, 25: 5591.